Abstract:Background Idiopathic pulmonary fibrosis (IPF) is a progressive and life-threatening lung disease with high mortality rates. The limited availability of effective drugs for IPF treatment, coupled with concerns regarding adverse effects and restricted responsiveness, underscores the need for alternative approaches. Kefir peptides (KPs) have demonstrated antioxidative, anti-inflammatory, and antifibrotic properties, along with the capability to modulate gut microbiota. This study aims to investigate the impact of KPs on bleomycin-induced pulmonary fibrosis. Methods Mice were treated with KPs for four days, followed by intratracheal injection of bleomycin for 21 days. Comprehensive assessments included pulmonary functional tests, micro-computed tomography (μ-CT), in vivo image analysis using MMPsense750, evaluation of inflammation- and fibrosis-related gene expression in lung tissue, and histopathological examinations. Furthermore, a detailed investigation of the gut microbiota community was performed using full-length 16 S rRNA sequencing in control mice, bleomycin-induced fibrotic mice, and KPs-pretreated fibrotic mice. Results In KPs-pretreated bleomycin-induced lung fibrotic mice, notable outcomes included the absence of significant bodyweight loss, enhanced pulmonary functions, restored lung tissue architecture, and diminished thickening of inter-alveolar septa, as elucidated by morphological and histopathological analyses. Concurrently, a reduction in the expression levels of oxidative biomarkers, inflammatory factors, and fibrotic indicators was observed. Moreover, 16 S rRNA sequencing demonstrated that KPs pretreatment induced alterations in the relative abundances of gut microbiota, notably affecting Barnesiella_intestinihominis , Kineothrix_alysoides , and Clostridium_viride . Conclusions Kefir peptides exerted preventive effects, protecting mice against bleomycin-induced lung oxidative stress, inflammation, and fibrosis. These effects are likely linked to modifications in the gut microbiota community. The findings highlight the therapeutic potential of KPs in mitigating pulmonary fibrosis and advocate for additional exploration in clinical settings.

Kynurenine Acts As a Signaling Molecule to Attenuate Pulmonary Fibrosis by Enhancing the AHR-PTEN Axis.

Kynurenine induces T cell fat catabolism and has limited suppressive effects in vivo

Klotho antagonizes pulmonary fibrosis through suppressing pulmonary fibroblasts activation, migration, and extracellular matrix production: a therapeutic implication for idiopathic pulmonary fibrosis

The Antihepatic Fibrotic Effects of Fluorofenidone Via Mapk Signalling Pathways

The role of the kynurenine pathway in cardiovascular disease

FAK-related nonkinase is a multifunctional negative regulator of pulmonary fibrosis.

Casein Kinase 1δ/ε Inhibitor, PF670462 Attenuates the Fibrogenic Effects of Transforming Growth Factor-β in Pulmonary Fibrosis

Adipocyte-derived kynurenine promotes obesity and insulin resistance by activating the AhR/STAT3/IL-6 signaling

AKT2 Regulates Pulmonary Inflammation and Fibrosis Via Modulating Macrophage Activation

Ketogenic diet induces autophagy to alleviate bleomycin-induced pulmonary fibrosis in murine models

Kefir peptides mitigate bleomycin-induced pulmonary fibrosis in mice through modulating oxidative stress, inflammation and gut microbiota

Kynurenine Attenuates Ulcerative Colitis Mediated by the Aryl Hydrocarbon Receptor

Tanshinone IIA Alleviates Pulmonary Fibrosis by Inhibiting Pyroptosis of Alveolar Epithelial Cells Through the MAPK Signaling Pathway

A Klotho-derived peptide protects against kidney fibrosis by targeting TGF-β signaling

Mutation of regulatory phosphorylation sites in PFKFB2 worsens renal fibrosis

PKM2/Hif-1α Signal Suppression Involved in Therapeutics of Pulmonary Fibrosis with Microcystin-Rr but Not with Pirfenidone

Kynurenine Promotes RANKL-Induced Osteoclastogenesis In Vitro by Activating the Aryl Hydrocarbon Receptor Pathway

1‐Hydroxypyrene mediates renal fibrosis through aryl hydrocarbon receptor signalling pathway

Tanshinone IIA ameliorates energy metabolism dysfunction of pulmonary fibrosis using 13C metabolic flux analysis

Upregulation of KLF14 Expression Attenuates Kidney Fibrosis by Inducing PPARα-Mediated Fatty Acid Oxidation

Kaempferol Reduces K63-linked Polyubiquitination to Inhibit Nuclear Factor-Κb and Inflammatory Responses in Acute Lung Injury in Mice.